Summary:
- The article discusses the positive results from Avacta Group's ESMO 2022 presentation, which showcased compelling data for its lead asset, AVA6000, a pre|CISION pro-drug of the chemotherapy doxorubicin.
- The data demonstrated that AVA6000 was well-tolerated and showed promising anti-tumor activity in patients with advanced solid tumors, including those who had previously received doxorubicin.
- The article highlights that the results support the continued development of AVA6000 and Avacta's precision medicine platform, which aims to improve the therapeutic index of chemotherapies and reduce side effects for cancer patients.